AgelessRx Broadens GLP-1 Weight Care Options to Advance Longevity-First Healthcare
This expansion reflects AgelessRx's mission to make science-backed, personalized longevity care more accessible, offering a range of clinically appropriate GLP-1 therapies that support better metabolic health and, in turn, potentially improve lifespan and healthspan.
Weight is one of the most modifiable risk factors affecting healthy aging. Elevated BMI is strongly associated with reduced life expectancy, insulin resistance, and age-related disease. For people who've struggled to achieve a lower BMI through lifestyle alone, GLP-1s have been a promising solution.
The GLP-1 category is projected to exceed $322.85 billion globally by 2034, with rapid growth at 21.3% CAGR, driven by public demand for obesity and metabolic health solutions that target the biology behind weight gain. As a longevity-first platform, AgelessRx is uniquely positioned to guide customers through safe, personalized use of these therapies as part of a broader preventative care model.
AgelessRx clinicians will evaluate eligibility and, if appropriate, prescribe Zepbound® for fulfillment via LillyDirect®, Eli Lilly's direct-to-patient pharmacy. AgelessRx will provide full prescription management and clinical oversight for $50/month, including titration guidance, side-effect monitoring, as well as ongoing care and education to provide an additional layer of longevity-focused support. If eligible, patients can access Zepbound® single-dose vials directly from LillyDirect®, starting at $349/month. AgelessRx is not affiliated with Eli Lilly or LillyDirect® and serves solely as the prescribing and care coordination provider to support patients through their treatment.
Recent topline results from the SURMOUNT-5 trial show the impact of Zepbound® (tirzepatide):
−20.2% average weight reduction with tirzepatide compared to -13.7% with semaglutide
47% greater relative reduction in weight
Over 31% of patients on tirzepatide achieved ≥25% weight loss
While full peer-reviewed results are pending, these findings reinforce growing evidence that dual GIP/GLP-1 receptor agonists like tirzepatide may offer significant metabolic benefits.
In addition to supporting access to Zepbound® via LillyDirect®, AgelessRx has also introduced Compounded Liraglutide + B12, a daily GLP-1 injectable. These two new treatments join several other metabolic health solutions, all of which are prescribed following a comprehensive evaluation and personalized plan, providing eligible customers with a diverse range of treatment options based on affordability, clinical fit, safety, and overall health goals.
For additional information about AgelessRx, please visit agelessrx.com.
*AgelessRx has no affiliation or partnership with Eli Lilly or LillyDirect®. AgelessRx's role is to provide clinical evaluation and prescription management for patients who meet the medical criteria for Zepbound®. Medication fulfillment is handled solely by LillyDirect®.
About AgelessRx
AgelessRx is at the forefront of the longevity revolution, offering clinically validated, cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram, X, and Facebook.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
19 hours ago
- CNBC
From Starbucks to Smoothie King, restaurants seek to cash in on consumers' protein frenzy
Restaurant chains are joining in on the protein frenzy, hoping to encourage diners to pay more for extra macronutrients during a time when many consumers aren't spending as much. From "gym bros" to users of GLP-1 drugs like Ozempic, many Americans are trying to add more protein to their diets, with the goal of building or maintaining their muscle mass and feeling more satiated after meals. Moreover, diet trends that don't emphasize protein intake, such as the ketogenic diet, have fallen out of favor. "A lot of younger consumers are more proactive about their health habits, so they're looking for ways to support health now but also to support their health in the future," said Julia Mills, a food and drink analyst for market research firm Mintel. "Generation Alpha, Gen Z, millennials — these consumers are very active on social media, so they're constantly being fed this message that you need more protein, and protein helps you gain muscle and makes you stronger." Roughly a third of consumers said they loved high protein in the second quarter of 2025, up from 24% three years ago, according to Datassential, which tracks restaurant menus and consumer preferences. The trend has fueled a protein takeover in grocery store aisles, from protein-packed Eggo waffles to Khloe Kardashian's Khloud protein popcorn. But it's also hitting the menus of restaurants that are seeking ways to encourage diners to pay for premium food and drinks. Take Starbucks, for example. The coffee giant said in late July that it will roll out a cold foam packed with 15 grams of protein later this year; the regular cold foam add-on typically costs customers an extra $1.25 per drink. The new foam comes as the chain's U.S. sales have been shrinking for the past year as coffee drinkers brew their java at home or seek out trendier options. Rival Dutch Bros launched a protein coffee in early 2024 and charges customers an extra $1 for the customization. The menu addition fueled strong same-store sales growth and profits for the upstart chain. Eateries are seeking to attract diners like Jared Hutkowski, a 42-year-old director of brokerage in Harrisburg, Pennsylvania. He works out six days a week and tries to hit his daily protein goal to improve his physique and overall health. When he dines out, he tries to maximize his protein, although he sometimes goes for pizza anyway. "The biggest factor is what I am in the mood for that day, and then I normally try and select a meal that has a least a serving of some type of protein in it," Hutkowski said. This year, 28.4% of U.S. restaurant menus call out "protein," up from 5.9% a decade ago, according to Datassential. And the trend looks like it has staying power. Datassential predicts that by 2029, more than 40% of eateries will highlight protein on their menus. "Protein is one of those things that's never been vilified, because no one's ever said that eating too much protein can be bad for you," Mintel's Mills said. In the short term, consuming more protein than your body needs likely won't cause health issues, but in the long term, it could cause kidney problems, according to Diane Han, a registered dietitian based in San Francisco and the founder of Woking Balance Wellness. The recommended daily amount of protein intake varies by body weight but is roughly 46 grams for women and 56 grams for men, according to the Centers for Disease Control and Prevention. For restaurants, protein's step change happened several years ago. In 2021, protein only had a menu penetration of 11.5%; by 2022, more than a quarter of restaurant menus used the term, based on Datassential data. That year, Dine Brands' IHOP, for example, introduced pancakes with 18 grams of protein per flapjack. Fast-casual eateries are the restaurant segment most likely to call out protein on their menus, thanks to the common practice of asking customers to pick their protein or offering to double their portion, according to Datassential. Fast-casual salad chain Sweetgreen introduced a line of "protein plates" in late 2023 as part of an effort to introduce more hearty options for dinner customers. The menu addition has helped the company grow its dinner business from 35% of sales to about 40%, executives said in March. Many restaurants are also leaning into U.S. consumers' desire for convenience. Accessibility may be why Datassential found that consumers tend to prefer protein-packed beverages. For Smoothie King, protein has been a menu staple since its founding more than 50 years ago. But in October, the chain took one step further, launching a menu aimed at consumers who take GLP-1 drugs for weight loss or diabetes. The rapid weight loss that can occur from the medications can cause muscle mass to drop, so doctors often advise patients to increase their protein intake to maintain their muscle. "It's a convenient, on-the-go way to get in your protein that you're looking for in your diet," said Lori Primavera, Smoothie King's vice president of research and development and product marketing. Many restaurants are also choosing to highlight existing protein-packed options, rather than adding new menu items that would slow down kitchens or add to much complexity to their operations. For example, Panda Express introduced its own protein plates earlier this year. The line, created in partnership with a registered dietitian, includes pre-existing menu items but packages them as a balanced meal, highlighting protein and fiber content. Chipotle Mexican Grill employed a similar strategy back in 2019 when it introduced "lifestyle bowls," marketed to fit different dietary goals, like the paleo diet or offering double protein. Likewise, in July, Chick-fil-A put the spotlight on its own high-protein options in a company blog, highlighting its grilled nuggets and the Cool Wrap, which features a grilled chicken breast, cheese and lettuce in a tortilla. But for the eateries that want to add new menu items, nachos with a choice of protein, restaurant-made protein bars and egg dishes that highlight high protein content are all increasingly popular options, according to Datassential trendologist Claire Conaghan. Eggs are one reason why breakfast, brunch and lunch eatery First Watch has always been "protein forward," CEO Chris Tomasso told CNBC. The chain hasn't adjusted its menu specifically to address consumers' demand for more protein, but TikTok influencers have highlighted how to order a high-protein meal when visiting its restaurants. "We hope that continues to be a trend because we're right down the middle of the fairway on that," Tomasso said. Of course, protein isn't the only way to win over health-conscious consumers. Hutkowski said his primary issue with eating at restaurants is that most of the food is cooked in oils, butter and heavy greases that rapidly add to his intake of fats for the day. "A restaurant finding cleaner ways to cook would be much more attractive to me than overly loaded protein dishes," he said.
Yahoo
20 hours ago
- Yahoo
Eli Lilly's Miracle Weight Loss Pill May Not Be Miraculous Enough
Eli Lilly shares looked like they'd been through an intensive Zepbound weight-loss treatment Thursday, losing 14% of their value on the New York Stock Exchange. Shareholders prefer their stocks to bulk up. The culprit was data for Lilly's weight loss pill, meant to expand the reach of its existing GLP-1 treatment for obesity. What it underscored is just how fierce, down to mere percentage points, the next several years of competition in the medical weight loss market will be. READ ALSO: Intel's CEO Lands in a Political Hot Seat Over Connections With China and Spacecraft-Maker Firefly Shoots for the Moon in Nasdaq Debut The Percentage Gap Lilly's second-quarter results reported Thursday were more than fine: $15.5 billion in revenue beat Wall Street estimates. And the company continued a streak of winning market share from its chief rival in the business of GLP-1s, which have been hailed as miracle drugs for their usefulness in treating diabetes and obesity. On Wednesday, Denmark's Novo Nordisk said GLP-1 diabetes drugs' sales growth slowed to just 8% in the second quarter, far behind the 21% posted last year. Sales of obesity drugs, including Wegovy, rose 56%, the same pace as last year. A day later, Lilly revealed that it continued to encroach on its rivals' market share in the second quarter, with Mounjaru revenue up 68% year-over-year to $5.2 billion and Zepbound revenue up 172% to $3.4 billion. The company raised its full-year guidance by $1.5 billion to between $60 billion and $62 billion. But then came the data everyone was anticipating. GLP-1s have become so popular that one in eight US adults, or 12%, told a poll by KFF Health last year that they had taken a GLP-1 drug before, while 6% said they were then using one. But the treatments are currently administered through a weekly injection, which companies say drives away patients averse to needles. To remedy that, Eli Lilly and Novo Nordisk have been developing GPL-1 pills, which could unlock billions in new sales. Morgan Stanley analysts previously said the bull case for Lilly's GLP-1 pill treatment for obesity and diabetes is $40 billion in annual sales by 2033. Thursday revealed a slight hitch: The pills have a problem: Lilly's orforglipron helped non-diabetic overweight or obese patients lose 12.4% of their weight in a late-stage study. Sounds great, except it's less than the 15% weight loss achieved by Novo Nordisk's oral version of Wegovy, for which that company is already seeking FDA approval. The performance gap was substantial enough to convince many investors that Novo's pill will have the upper hand when the two go to market. After the data was released, one analyst — David Risinger of Leerink Partners — cut his forecast for orforglipron's 2030 sales by 38% to $13.5 billion. And the Winner Is: Novo, at least for a day. Losing market share to Lilly and copycat drugmakers has weighed heavily on the company, with its shares falling over 43% this year. The news of the muted performance of its chief rival's GLP-1 pill sent Novo's shares up 7.5% on Thursday. Both treatments are still expected to be big earners, but Novo — which has also had to tangle with tariff threats this year, unlike US-based Lilly — can claim another small victory in the race to produce the biggest (weight) loser. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Initial results show promise for Eli Lilly's new weight loss drug
A new weight loss pill made by Eli Lilly helped people lose a significant amount of weight in a recent study. Taken at the highest dose, orforglipron helped patients lose an average 27.3 pounds, or 12.4% of their body weight, over 72 weeks. Eli Lilly says it plans to apply for U.S. Food and Drug Administration approval by the end of the year to market the drug. If approved, the pill could become a simpler alternative to injectable medications like Wegovy, Ozempic, Zepbound and Mounjaro, which are used to treat obesity and type 2 diabetes. Pills are easier to make and "can be manufactured at a significant scale," Kenneth Custer, Eli Lilly's president of cardiometabolic health, told The New York Times. "There are orders of magnitude differences in how many we can support," he said, adding that pills could also help people in countries without access to cold storage needed for injected drugs. Like the injected medications, the new pill belongs to the GLP-1 class of drugs. GLP-1 drugs work by helping people feel full longer and by slowing digestion, according to the Cleveland Clinic. The recent study included 3,127 adults who were randomly assigned to take orforglipron or a placebo. Three different dosages of the drug were evaluated. In addition to weight loss, people taking the drug also saw improvements in cholesterol, triglyceride levels and blood pressure. Side effects were similar to those seen with injectable drugs and included vomiting, diarrhea, constipation and indigestion, The Times said. Earlier this year, Lilly also tested orforglipron in people with type 2 diabetes and found that it lowered blood sugar and led to weight loss similar to Ozempic. The company plans to seek FDA approval to market the drug for diabetes use in 2026, The Times reported. Orforglipron has not yet been compared directly with injected drugs like Wegovy or Zepbound. In a previous study, Zepbound helped people lose 20.2% of their weight, and Wegovy led to a 13.2% weight loss over 72 weeks. Still, experts say the new pill may have key benefits. It may not be as powerful as injections, though, said Dr. David Cummings, an obesity expert at the University of Washington in Seattle. But if it's a lot cheaper and easier to make, Cummings said, then "that feature alone could make it truly impactful." Eli Lilly has not yet said how much the pill will cost, and plans to decide after the FDA reviews it for marketing approval. About 8 million Americans now take obesity medications, even though an estimated 170 million could benefit, according to Custer. He said a major reason is that making injected drugs is expensive and slow, The Times said. Because pills are easier to make and store, this new drug could help reach more people, Custer added. More information Learn more about Eli Lilly's mission. Copyright © 2025 HealthDay. All rights reserved.
